Analyst Viewpoint
Increase in adoption of advanced skincare procedures, led by rise in awareness about skin conditions among the global population, is a key factor that is bolstering the pigmentation disorder treatment market size. Surge in pigmentation cases owing to excessive exposure to sun, skin injuries, and inflammation is also augmenting market progress. People are increasingly opting for skin treatments such as laser therapy and chemical peels, as these are safer and offer quicker results. However, high cost of these treatments is hampering the pigmentation disorder treatment industry revenue to some extent.
Companies operating in the sector are launching novel drugs and therapies to expand their client base. In line with the latest pigmentation disorder treatment market trends, key players are striving to introduce advanced treatment modalities to improve the outcome of these procedures.
Pigmentation is a skin condition that adversely affects the color of the skin. Melasma, albinism, and vitiligo are some of the common types of pigmentation disorders. Skin pigmentation can occur in patches or across the body.
Albinism, a genetic disorder, is caused by defects in genes that provide instructions for melanin production. Body is unable to produce or distribute melanin due to several genetic defects. Lack of color in skin, hair, or eyes is the primary symptom of albinism.
Melasma, a common skin pigmentation disorder, is also referred to as chloasma or the ‘mask of pregnancy.’ It is a common skin condition that usually affects women. People with darker skin tones are more likely to be affected by melasma.
Discoloration of skin can also occur due to skin damage. Burns and wounds can result in skin pigmentation that is permanent or long-lasting, depending upon the severity.
Adoption of advanced medical procedures, such as skin treatments, has been rising across the globe, as people are increasingly upgrading their lifestyle. Rise in disposable income is also leading to a growth in adoption of advanced medical treatments. Furthermore, increase in awareness about skin disorders is creating lucrative pigmentation disorder treatment business opportunities for companies operating in the sector.
Several types of pigmentation disorder treatments such as laser therapy, chemical peels, and micro-needling have been introduced lately in the market. These are quite safe and offer improved and quick results. For instance, utilization of latest picosecond laser has boosted the pigmentation disorder treatment industry. Ultra-short light pulses from picosecond lasers can precisely target and remove pigment particles from the pigmented area without damaging or harming the surrounding skin.
Compared to conventional nanosecond lasers, these lasers have lesser side effects, quicker treatment periods, and greater efficacy, which has made them quite popular. Thus, rise in adoption of newer and advanced skin treatments is boosting pigmentation disorder treatment market dynamics.
According to Karger Journal study, people from Latin America and African heritage are more prone to pigmentation disorders. Significant population in Asia Pacific, especially in China and India, also faces high incidence of pigmentation problems.
The Karger journal study further states that pigmentation disorders rank third and fourth among dermatoses, which largely affects the Hispanic population.
The global pigmentation disorder treatment market is expected to grow at a steady pace in the near future due to increase in research and development initiatives by key players. For instance, in July 2022, Ahammune Biosciences and Veeda Clinical Research Limited entered into a partnership for first-in-human studies with Ahammune’s investigational new drug -AB1001 - being developed as a topical therapy for vitiligo.
Rise in government investment in healthcare and biotechnology industries in developing countries is also likely to augment the pigmentation disorder treatment market during the forecast period.
Asia Pacific accounted for significant pigmentation disorder treatment market share in 2022. People in the region are more inclined to seek treatment for pigmentation disorders as a result of growth in concerns about skin and appearance and rise in disposable income.
Several countries in Asia Pacific have been experiencing rapid urbanization, which has led to changes in lifestyle and increase in exposure to environmental factors such as pollution, high temperatures, and even global warming that might worsen pigmentation issues.
People living in the urban areas in Asia Pacific have easy access to healthcare facilities and dermatologists. Increase in awareness about skin health, presence of developed healthcare facilities, and availability of modern medical treatments are also augmenting market statistics in Asia Pacific.
Leading pigmentation disorder treatment market manufacturers are investing significantly in the manufacture of highly effective skincare products to expand their product portfolio and increase their industry share. They are also engaged in clinical trials to develop drugs and treatments that reduce discoloration by protecting the skin from external aggressors.
Bayer AG, Galderma S.A. (Nestle Skin Health S.A), SkinCeuticals, Pierre Fabre, EpiPharm AG, RXi Pharmaceuticals Corporation, Obagi Cosmeceuticals LLC (Obagi Medical), and Vivier Pharma are some of the prominent manufacturers of pigmentation disorder treatment drugs.
Each of these players has been profiled in the pigmentation disorder treatment market report based on parameters such as company overview, business strategies, financial overview, business segments, product portfolio, and recent developments.
| Attribute | Detail |
|---|---|
| Market Size in 2022 | US$ 6.8 Bn |
| Market Forecast (Value) in 2031 | US$ 10.6 Bn |
| Growth Rate (CAGR) | 5.2% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional-level analysis. Furthermore, the qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces Analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
It was valued at US$ 6.8 Bn in 2022
It is anticipated to grow at a CAGR of 5.2% from 2023 to 2031
Increase in adoption of advanced medical procedures, rise in prevalence of pigmentation cases, and growth in R&D initiatives
The topical drugs treatment segment held the largest share in 2022
Asia Pacific was the leading region in 2022
Bayer AG, Galderma S.A. (Nestle Skin Health S.A.), SkinCeuticals, Pierre Fabre, EpiPharm AG, RXi Pharmaceuticals Corporation, Obagi Cosmeceuticals LLC (Obagi Medical), Vivier Pharma
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Pigmentation Disorder Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Pigmentation Disorder Treatment Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Pigmentation Disorder Treatment Market Analysis and Forecast, by Treatment
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Treatment, 2017–2031
6.3.1. Topical Drugs
6.3.2. Laser Therapy
6.3.3. Chemical Peels
6.3.4. Microdermabrasion
6.3.5. Phototherapy
6.3.6. Others
6.4. Market Attractiveness Analysis, by Treatment
7. Global Pigmentation Disorder Treatment Market Analysis and Forecast, by Disease Indication
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Disease Indication, 2017–2031
7.3.1. Hypopigmentation
7.3.1.1. Vitiligo
7.3.1.2. Albinism
7.3.1.3. Others
7.3.2. Hyperpigmentation
7.3.2.1. Melasma
7.3.2.2. Post-inflammatory Hyperpigmentation
7.3.2.3. Solar Lentigines
7.3.2.4. Others
7.4. Market Attractiveness Analysis, by Disease Indication
8. Global Pigmentation Disorder Treatment Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2017–2031
8.3.1. Hospitals
8.3.2. Aesthetic Clinics & Dermatology Centers
8.3.3. Others
8.4. Market Attractiveness Analysis, by Disease Indication
9. Global Pigmentation Disorder Treatment Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Pigmentation Disorder Treatment Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Treatment, 2017–2031
10.3.1. Topical Drugs
10.3.2. Laser Therapy
10.3.3. Chemical Peels
10.3.4. Microdermabrasion
10.3.5. Phototherapy
10.3.6. Others
10.4. Market Value Forecast, by Disease Indication, 2017–2031
10.4.1. Hypopigmentation
10.4.1.1. Vitiligo
10.4.1.2. Albinism
10.4.1.3. Others
10.4.2. Hyperpigmentation
10.5. Melasma
10.5.1. Post-inflammatory Hyperpigmentation
10.5.2. Solar Lentigines
10.5.3. Others
10.6. Market Value Forecast, by End-user, 2017–2031
10.6.1. Hospitals
10.6.2. Aesthetic Clinics & Dermatology Centers
10.6.3. Others
10.7. Market Value Forecast, by Country, 2017–2031
10.7.1. U.S.
10.7.2. Canada
10.8. Market Attractiveness Analysis
10.8.1. By Treatment
10.8.2. By Disease Indication
10.8.3. By End-user
10.8.4. By Country
11. Europe Pigmentation Disorder Treatment Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Treatment, 2017–2031
11.3.1. Topical Drugs
11.3.2. Laser Therapy
11.3.3. Chemical Peels
11.3.4. Microdermabrasion
11.3.5. Phototherapy
11.3.6. Others
11.4. Market Value Forecast, by Disease Indication, 2017–2031
11.4.1. Hypopigmentation
11.4.1.1. Vitiligo
11.4.1.2. Albinism
11.4.1.3. Others
11.4.2. Hyperpigmentation
11.4.2.1. Melasma
11.4.2.2. Post-inflammatory Hyperpigmentation
11.4.2.3. Solar Lentigines
11.4.2.4. Others
11.5. Market Value Forecast, by End-user, 2017–2031
11.5.1. Hospitals
11.5.2. Aesthetic Clinics & Dermatology Centers
11.5.3. Others
11.6. Market Value Forecast, by Country/Sub-region, 2017–2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Treatment
11.7.2. By Disease Indication
11.7.3. By End-user
11.7.4. By Country/Sub-region
12. Asia Pacific Pigmentation Disorder Treatment Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Treatment, 2017–2031
12.3.1. Topical Drugs
12.3.2. Laser Therapy
12.3.3. Chemical Peels
12.3.4. Microdermabrasion
12.3.5. Phototherapy
12.3.6. Others
12.4. Market Value Forecast, by Disease Indication, 2017–2031
12.4.1. Hypopigmentation
12.4.1.1. Vitiligo
12.4.1.2. Albinism
12.4.1.3. Others
12.4.2. Hyperpigmentation
12.4.2.1. Melasma
12.4.2.2. Post-inflammatory Hyperpigmentation
12.4.2.3. Solar Lentigines
12.4.2.4. Others
12.5. Market Value Forecast, by End-user, 2017–2031
12.5.1. Hospitals
12.5.2. Aesthetic Clinics & Dermatology Centers
12.5.3. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Treatment
12.7.2. By Disease Indication
12.7.3. By End-user
12.7.4. By Country/Sub-region
13. Latin America Pigmentation Disorder Treatment Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Treatment, 2017–2031
13.3.1. Topical Drugs
13.3.2. Laser Therapy
13.3.3. Chemical Peels
13.3.4. Microdermabrasion
13.3.5. Phototherapy
13.3.6. Others
13.4. Market Value Forecast, by Disease Indication, 2017–2031
13.4.1. Hypopigmentation
13.4.1.1. Vitiligo
13.4.1.2. Albinism
13.4.1.3. Others
13.4.2. Hyperpigmentation
13.4.2.1. Melasma
13.4.2.2. Post-inflammatory Hyperpigmentation
13.4.2.3. Solar Lentigines
13.5. Others
13.6. Market Value Forecast, by End-user, 2017–2031
13.6.1. Hospitals
13.6.2. Aesthetic Clinics & Dermatology Centers
13.6.3. Others
13.7. Market Value Forecast, by Country/Sub-region, 2017–2031
13.7.1. Brazil
13.7.2. Mexico
13.7.3. Rest of Latin America
13.8. Market Attractiveness Analysis
13.8.1. By Treatment
13.8.2. By Disease Indication
13.8.3. By End-user
13.8.4. By Country/Sub-region
14. Middle East & Africa Pigmentation Disorder Treatment Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Treatment, 2017–2031
14.3.1. Topical Drugs
14.3.2. Laser Therapy
14.3.3. Chemical Peels
14.3.4. Microdermabrasion
14.3.5. Phototherapy
14.3.6. Others
14.4. Market Value Forecast, by Disease Indication, 2017–2031
14.4.1. Hypopigmentation
14.4.1.1. Vitiligo
14.4.1.2. Albinism
14.4.1.3. Others
14.4.2. Hyperpigmentation
14.4.2.1. Melasma
14.4.2.2. Post-inflammatory Hyperpigmentation
14.4.2.3. Solar Lentigines
14.4.2.4. Others
14.5. Market Value Forecast, by End-user, 2017–2031
14.5.1. Hospitals
14.5.2. Aesthetic Clinics & Dermatology Centers
14.5.3. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Treatment
14.7.2. By Disease Indication
14.7.3. By End-user
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Bayer AG
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Galderma S.A. (Nestle Skin Health S.A)
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. SkinCeuticals
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Pierre Fabre
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. EpiPharm AG
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. RXi Pharmaceuticals Corporation
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Obagi Cosmeceuticals LLC (Obagi Medical)
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Vivier Pharma
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
List of Tables
Table 01: Global Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2031
Table 02: Global Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2017–2031
Table 03: Global Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 04: Global Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Country, 2017–2031
Table 06: North America Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2031
Table 07: North America Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2017–2031
Table 08: North America Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 09: Europe Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Europe Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2031
Table 11: Europe Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2017–2031
Table 12: Europe Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 13: Asia Pacific Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Asia Pacific Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2031
Table 15: Asia Pacific Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2017–2031
Table 16: Asia Pacific Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 17: Latin America Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 18: Latin America Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2031
Table 19: Latin America Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2017–2031
Table 20: Latin America Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 21: Middle East & Africa Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Middle East & Africa Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2031
Table 23: Middle East & Africa Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2017–2031
Table 24: Middle East & Africa Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by End-user, 2017–2031
List of Figures
Figure 01: Global Pigmentation Disorder Treatment Market Size (US$ Mn) and Distribution (%), by Region, 2017 and 2031
Figure 02: Global Pigmentation Disorder Treatment Market Revenue (US$ Mn), by Treatment, 2022
Figure 03: Global Pigmentation Disorder Treatment Market Value Share, by Treatment, 2022
Figure 04: Global Pigmentation Disorder Treatment Market Revenue (US$ Mn), by Disease Indication, 2022
Figure 05: Global Pigmentation Disorder Treatment Market Value Share, by Disease Indication, 2022
Figure 06: Global Pigmentation Disorder Treatment Market Revenue (US$ Mn), by End-user, 2022
Figure 07: Global Pigmentation Disorder Treatment Market Value Share, by End-user, 2022
Figure 08: Global Pigmentation Disorder Treatment Market Value Share, by Region, 2022
Figure 09: Global Pigmentation Disorder Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 10: Global Pigmentation Disorder Treatment Market Value Share Analysis, by Treatment, 2017 and 2031
Figure 11: Global Pigmentation Disorder Treatment Market Attractiveness Analysis, by Treatment, 2017-2031
Figure 12: Global Pigmentation Disorder Treatment Market Value Share Analysis, by Disease Indication, 2017 and 2031
Figure 13: Global Pigmentation Disorder Treatment Market Attractiveness Analysis, by Disease Indication, 2022-2031
Figure 14: Global Pigmentation Disorder Treatment Market Value Share Analysis, by End-user, 2017 and 2031
Figure 15: Global Pigmentation Disorder Treatment Market Attractiveness Analysis, by End-user, 2017-2031
Figure 16: Global Pigmentation Disorder Treatment Market Value Share Analysis, by Region, 2017 and 2031
Figure 17: Global Pigmentation Disorder Treatment Market Attractiveness Analysis, by Region, 2017-2031
Figure 18: North America Pigmentation Disorder Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 19: North America Pigmentation Disorder Treatment Market Attractiveness Analysis, by Country, 2017–2031
Figure 20: North America Pigmentation Disorder Treatment Market Value Share Analysis, by Country, 2017 and 2031
Figure 21: North America Pigmentation Disorder Treatment Market Value Share Analysis, by Treatment, 2017 and 2031
Figure 22: North America Pigmentation Disorder Treatment Market Value Share Analysis, by Disease Indication, 2017 and 2031
Figure 23: North America Pigmentation Disorder Treatment Market Value Share Analysis, by End-user, 2017 and 2031
Figure 24: North America Pigmentation Disorder Treatment Market Attractiveness Analysis, by Treatment, 2017–2031
Figure 25: North America Pigmentation Disorder Treatment Market Attractiveness Analysis, by Disease Indication, 2017–2031
Figure 26:North America Pigmentation Disorder Treatment Market Attractiveness Analysis, by End-user, 2022–2031
Figure 27: Europe Pigmentation Disorder Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 28: Europe Pigmentation Disorder Treatment Market Attractiveness Analysis, by Country/Sub-region, 2017–2031
Figure 29: Europe Pigmentation Disorder Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
Figure 30: Europe Pigmentation Disorder Treatment Market Value Share Analysis, by Treatment, 2017 and 2031
Figure 31: Europe Pigmentation Disorder Treatment Market Value Share Analysis, by Disease Indication, 2017 and 2031
Figure 32: Europe Pigmentation Disorder Treatment Market Value Share Analysis, by End-user, 2017 and 2031
Figure 33: Europe Pigmentation Disorder Treatment Market Attractiveness Analysis, by Treatment, 2017–2031
Figure 34: Europe Pigmentation Disorder Treatment Market Attractiveness Analysis, by Disease Indication, 2017–2031
Figure 35: Europe Pigmentation Disorder Treatment Market Attractiveness Analysis, by End-user, 2017–2031
Figure 36: Asia Pacific Pigmentation Disorder Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 37: Asia Pacific Pigmentation Disorder Treatment Market Attractiveness Analysis, by Country/Sub-region, 2017–2031
Figure 38: Asia Pacific Pigmentation Disorder Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
Figure 39: Asia Pacific Pigmentation Disorder Treatment Market Value Share Analysis, by Treatment, 2017 and 2031
Figure 40: Asia Pacific Pigmentation Disorder Treatment Market Value Share Analysis, by Disease Indication, 2017 and 2031
Figure 41: Asia Pacific Pigmentation Disorder Treatment Market Value Share Analysis, by End-user, 2017 and 2031
Figure 42: Asia Pacific Pigmentation Disorder Treatment Market Attractiveness Analysis, by Treatment, 2017–2031
Figure 43: Asia Pacific Pigmentation Disorder Treatment Market Attractiveness Analysis, by Disease Indication, 2017–2031
Figure 44: Asia Pacific Pigmentation Disorder Treatment Market Attractiveness Analysis, by End-user, 2017–2031
Figure 45: Latin America Pigmentation Disorder Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 46: Latin America Pigmentation Disorder Treatment Market Attractiveness Analysis, by Country/Sub-region, 2017–2031
Figure 47: Latin America Pigmentation Disorder Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
Figure 48: Latin America Pigmentation Disorder Treatment Market Value Share Analysis, by Treatment, 2017 and 2031
Figure 49: Latin America Pigmentation Disorder Treatment Market Value Share Analysis, by Disease Indication, 2017 and 2031
Figure 50: Latin America Pigmentation Disorder Treatment Market Value Share Analysis, by End-user, 2017 and 2031
Figure 51: Latin America Pigmentation Disorder Treatment Market Attractiveness Analysis, by Treatment, 2017–2031
Figure 52: Latin America Pigmentation Disorder Treatment Market Attractiveness Analysis, by Disease Indication, 2017–2031
Figure 53: Latin America Pigmentation Disorder Treatment Market Attractiveness Analysis, by End-user, 2017–2031
Figure 54: Middle East & Africa Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 55: Middle East & Africa Pigmentation Disorder Treatment Market Attractiveness Analysis, by Country/Sub-region, 2017–2031
Figure 56: Middle East & Africa Pigmentation Disorder Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
Figure 57: Middle East & Africa Pigmentation Disorder Treatment Market Value Share Analysis, by Treatment, 2017 and 2031
Figure 58: Middle East & Africa Pigmentation Disorder Treatment Market Value Share Analysis, by Disease Indication, 2017 and 2031
Figure 59: Middle East & Africa Pigmentation Disorder Treatment Market Value Share Analysis, by End-user, 2017 and 2031
Figure 60: Middle East & Africa Pigmentation Disorder Treatment Market Attractiveness Analysis, by Treatment, 2017–2031
Figure 61: Middle East & Africa Pigmentation Disorder Treatment Market Attractiveness Analysis, by Disease Indication, 2017–2031
Figure 62: Middle East & Africa Pigmentation Disorder Treatment Market Attractiveness Analysis, by End-user, 2017–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Pigmentation Disorder Treatment Market
